Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy

Inclusion Criteria: * Type2 diabetes patients * Age \<30yrs-70yrs\> * Overt proteinuria (Urinary protein creatinine ratio \> 200mg/g 2 times or more during past 6 Mo) * Scr \< 2.5 mg/dL * HbA1C \< 7.5 * Systolic blood pressure \> 160 mmHg without antihypertensive drugs or \> 140 with antihypertensive drug * No history of previous cardiovascular event (Stroke, Myocardial infarction, unstable angina, hospitalization, surgical correction PVD or PVD with claudication) * No hospitalization within 1 yr except for elective surgery Exclusion Criteria: * Physical examination found or suspected serious co-morbid (AF, carotid bruit, structural heart disease, cirrhosis and decompensate liver disease) * Non adherence to protocol * Intolerable to ACEI or ARB during run-in * Abnormal liver function test at the run-in period * Rapid declining renal function (SCr increase \> 40%) during run-in * Hyperkalemia (serum K \> 5.5 mEq/L at randomization) * Malignancy detected o * SBP lower than 110 mmHg (at randomization)